Barclays PLC Purchases 8,713 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Barclays PLC boosted its holdings in Zynex, Inc. (NASDAQ:ZYXI) by 43.3% in the third quarter, HoldingsChannel reports. The firm owned 28,821 shares of the company’s stock after purchasing an additional 8,713 shares during the period. Barclays PLC’s holdings in Zynex were worth $236,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Gladius Capital Management LP increased its stake in shares of Zynex by 53.4% in the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock valued at $41,000 after acquiring an additional 1,742 shares in the last quarter. Investment Partners Asset Management Inc. acquired a new position in Zynex during the 3rd quarter worth approximately $96,000. Hsbc Holdings PLC acquired a new stake in Zynex in the 2nd quarter valued at $113,000. Quest Partners LLC increased its stake in Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after purchasing an additional 11,195 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Zynex by 10.4% during the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after buying an additional 1,846 shares during the last quarter. 29.68% of the stock is owned by institutional investors and hedge funds.

Zynex Stock Performance

NASDAQ:ZYXI opened at $8.09 on Monday. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The company has a market capitalization of $257.63 million, a P/E ratio of 53.93 and a beta of 0.49. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The business has a fifty day simple moving average of $8.30 and a two-hundred day simple moving average of $8.36.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. During the same period in the prior year, the firm earned $0.10 earnings per share. The company’s revenue was up .1% compared to the same quarter last year. On average, analysts expect that Zynex, Inc. will post 0.2 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $7.88, for a total transaction of $78,800.00. Following the completion of the transaction, the chief financial officer now owns 26,299 shares of the company’s stock, valued at approximately $207,236.12. The trade was a 27.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 44,000 shares of company stock worth $368,040 in the last quarter. 52.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th. Royal Bank of Canada dropped their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.